Previous 10 | Next 10 |
Alnylam Pharmaceuticals ([[ALNY]] -0.4%) reports Q4 total revenues of $163.56M, an increase 128.2% Y/Y, beats consensus by $15.85M.Combined net product revenues were $112.8M in Q4, representing 102% growth from last year, the strong growth primarily resulted from an incre...
Alnylam Pharmaceuticals (ALNY): Q4 Non-GAAP EPS of -$1.60 misses by $0.22; GAAP EPS of -$2.09 misses by $0.33.Revenue of $163.56M (+128.2% Y/Y) beats by $15.85M.Shares -3.8% PM.Press Release For further details see: Alnylam Pharmaceuticals EPS misses by $0.22, beats on revenue
− Achieved Fourth Quarter and Full Year 2020 Global Net Product Revenues of $113 Million and $362 Million, Respectively – − Achieved Regulatory Approvals of OXLUMO™ in the EU and U.S. and Leqvio®, by Partner Novartis, in the EU – ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to announce Q4 earnings results on Thursday, February 11th, before market open.The consensus EPS Estimate is -$1.38 (+30.3% Y/Y) and the consensus Revenue Estimate is $147.06M.Over the last 2 years, ALNY has beaten EPS estimates 38% of the ti...
Gainers: [[GLUU]] +33.8%. [[CCLP]] +24.9%. [[TRITW]] +15.3%. [[VRNS]] +8.6%. [[ZNGA]] +6.8%.Losers: [[INFI]] -26.7%. [[ALNY]] -17.4%. [[ITCI]] -10.7%. [[AAME]] -7.9%. [[TTOO]] -6.3%. For further details see: GLUU, CCLP, AAME and INFI among after-hours movers
In the last few days, the question of why more drug companies haven't been enlisted for vaccine production has come up. There are not "dozens of other pharma companies" who "stand ready" to produce these mRNA vaccines. Sanofi, one of the big vaccine players already (and one with t...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2020 on Thursday, February 11, 2021, before the U.S. financial markets open. Management ...
Having overcome business challenges presented by the COVID-19 pandemic, the stock of Alexion Pharmaceuticals (ALXN) has been hitting new highs. We think it may be wise to bet on the stock now because this company has been receiving multiple regulatory approvals for its products. Headquart...
Alnylam Pharmaceuticals ([[ALNY]] -0.3%) is trading flat after BMO Capital Markets downgraded the stock to market perform from outperform, noting that the stock priced in near-term commercial success in January after a steep climb in one week.Early this month, Alnylam announced positive ...
A question that comes up a lot about mRNA vaccines is what happens at the cellular level after you're injected with one. The mechanism of any such vaccine is to cause cells to produce a viral protein antigen, but which cells actually do this? Let's dive into some details. But whil...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...